Alzamend Neuro, Inc.
ALZN
$2.15
-$0.05-2.27%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.06M | 3.29M | 3.08M | 3.06M | 3.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.87M | 6.23M | 4.50M | 4.21M | 5.83M |
| Operating Income | -5.87M | -6.23M | -4.50M | -4.21M | -5.83M |
| Income Before Tax | -5.88M | -6.24M | -4.51M | -4.23M | -5.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.88 | -6.24 | -4.51 | -4.23 | -5.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.88M | -6.24M | -4.51M | -4.23M | -5.85M |
| EBIT | -5.87M | -6.23M | -4.50M | -4.21M | -5.83M |
| EBITDA | -5.79M | -6.17M | -4.45M | -4.16M | -5.78M |
| EPS Basic | -5.71 | -8.88 | -19.02 | -27.72 | -60.00 |
| Normalized Basic EPS | -3.05 | -5.03 | -11.37 | -17.33 | -37.50 |
| EPS Diluted | -5.71 | -8.88 | -19.02 | -27.72 | -60.00 |
| Normalized Diluted EPS | -3.05 | -5.03 | -11.37 | -17.33 | -37.50 |
| Average Basic Shares Outstanding | 6.81M | 3.82M | 1.80M | 1.17M | 632.60K |
| Average Diluted Shares Outstanding | 6.81M | 3.82M | 1.80M | 1.17M | 632.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |